gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TGTXHealthcarePharmaceuticals

TG Therapeutics, Inc. (TGTX)

$61.63+1.45%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$60.75▲ 80.32% in range
Nov 3, 2025Low $26.94 · High $61.18Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

TG Therapeutics closed at $61.63 on Nov 4, up 1.45% — matching its 52-week closing high. Volume of 2.0M shares was 1.30× its 20-day average (above normal).

Split-adjusted performance: +18.1% over one month, +46.8% over six months, +82.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $240.34M, up 70.3% from a year earlier, with a net margin of 3.2%.

Short interest was 29.6M shares at the Oct 15 settlement, down 3.4% from the prior report (20.1% of float, 18.9 days to cover).

Market cap$9.43B153.1M shares
Revenue · quarter$240.3M+70.3% YoY
Diluted EPS$0.05−70.6% YoY
P/E · TTM21.4×P/S 11.8×
Net margin3.2%Gross 82.9%
Dividend yieldNone
52-week range26.94 – 61.630.0% from high
Volume2.0M1.30× 20-day avg
Volatility · 60d36.8%Annualised
Short % of float20.1%18.9 days to cover
Net cash-$193.1MCash $552.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +7.4%1M +18.1%3M +24.4%6M +46.8%YTD +106.7%1Y +82.9%3Y +734.0%5Y +98.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum92
Revenue growth82
Net margin73
Value (low P/E)38
Size95

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short29.6M−3.4% vs prior
Days to cover18.9Settled Oct 15
% of float20.1%
Short vol. 10d51.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TGTXTG Therapeutics$61.63+1.45%+46.8%+70.3%3.2%21.4$9.43B
PTGXProtagonist Therapeutics$143.37+2.23%+37.9%+3749.2%76.3%111.9$9.28BCompare
SYRESpyre Therapeutics$99.04−0.23%+35.7%———$9.26BCompare
MDGLMadrigal Pharmaceuticals$400.43+1.04%−25.8%+50.1%12.9%—$9.25BCompare
CYTKCytokinetics$63.60+2.07%−15.0%−57.1%−694.4%—$8.84BCompare
ARWRArrowhead Research$61.65+3.56%−22.1%+171.0%−258.2%—$8.71BCompare
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56BCompare
BMRNBioMarin Pharmaceuticals$57.13+2.64%+4.6%+19.9%4.5%151.5$11.06BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare

News about TG Therapeutics

All news →
TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research · Oct 26, 2026▲ PositiveTGTX Stock Rises 60% in 6 Months: Here's What You Should KnowZacks Investment Research · Oct 13, 2026▲ PositiveTG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?Zacks Investment Research · Sep 2, 2026NeutralKuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law FirmGlobeNewswire Inc. · Jul 17, 2026▼ Negative

Quick answers

What does TG Therapeutics do?
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S.
What is TGTX's market cap?
$9.43B, based on the Nov 4 close of $61.63.
What is TGTX's P/E ratio?
21.4× trailing-twelve-month earnings of $441.49M.
Does TG Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TGTX is sold short?
29.6M shares, 20.1% of float, as of Oct 15, 2026.
What sector is TGTX in?
Healthcare, in the Pharmaceuticals industry.

About TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

HQ: New York, NY399 employeesListed Dec 14, 1995tgtherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology